199 related articles for article (PubMed ID: 8360934)
1. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer.
Kohler MF; Marks JR; Wiseman RW; Jacobs IJ; Davidoff AM; Clarke-Pearson DL; Soper JT; Bast RC; Berchuck A
J Natl Cancer Inst; 1993 Sep; 85(18):1513-9. PubMed ID: 8360934
[TBL] [Abstract][Full Text] [Related]
2. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
Liu FS; Kohler MF; Marks JR; Bast RC; Boyd J; Berchuck A
Obstet Gynecol; 1994 Jan; 83(1):118-24. PubMed ID: 8272291
[TBL] [Abstract][Full Text] [Related]
3. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
[TBL] [Abstract][Full Text] [Related]
4. p53 mutations in ovarian cancer: a late event?
Mazars R; Pujol P; Maudelonde T; Jeanteur P; Theillet C
Oncogene; 1991 Sep; 6(9):1685-90. PubMed ID: 1923532
[TBL] [Abstract][Full Text] [Related]
5. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer.
Okamoto A; Sameshima Y; Yokoyama S; Terashima Y; Sugimura T; Terada M; Yokota J
Cancer Res; 1991 Oct; 51(19):5171-6. PubMed ID: 1680546
[TBL] [Abstract][Full Text] [Related]
6. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis.
Naito M; Satake M; Sakai E; Hirano Y; Tsuchida N; Kanzaki H; Ito Y; Mori T
Jpn J Cancer Res; 1992 Oct; 83(10):1030-6. PubMed ID: 1333465
[TBL] [Abstract][Full Text] [Related]
7. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma.
Kim JW; Cho YH; Kwon DJ; Kim TE; Park TC; Lee JM; Namkoong SE
Gynecol Oncol; 1995 May; 57(2):199-204. PubMed ID: 7729734
[TBL] [Abstract][Full Text] [Related]
8. Is it possible to diagnose malignancy from fluid in cystic ovarian tumors?
Yamada R; Maeda N; Oguri H; Adachi Y; Takeuchi T; Furihata M; Fukaya T
Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):96-100. PubMed ID: 24017961
[TBL] [Abstract][Full Text] [Related]
9. p53 expression, mutation, and allelic deletion in ovarian cancer.
McManus DT; Yap EP; Maxwell P; Russell SE; Toner PG; McGee JO
J Pathol; 1994 Nov; 174(3):159-68. PubMed ID: 7823248
[TBL] [Abstract][Full Text] [Related]
10. Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma.
Sameshima Y; Tsunematsu Y; Watanabe S; Tsukamoto T; Kawa-ha K; Hirata Y; Mizoguchi H; Sugimura T; Terada M; Yokota J
J Natl Cancer Inst; 1992 May; 84(9):703-7. PubMed ID: 1569604
[TBL] [Abstract][Full Text] [Related]
11. p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases.
Yamada Y; Yoshida T; Hayashi K; Sekiya T; Yokota J; Hirohashi S; Nakatani K; Nakano H; Sugimura T; Terada M
Cancer Res; 1991 Nov; 51(21):5800-5. PubMed ID: 1933850
[TBL] [Abstract][Full Text] [Related]
12. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers.
Hartmann A; Blaszyk H; McGovern RM; Schroeder JJ; Cunningham J; De Vries EM; Kovach JS; Sommer SS
Oncogene; 1995 Feb; 10(4):681-8. PubMed ID: 7862445
[TBL] [Abstract][Full Text] [Related]
13. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
15. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
Buller RE; Lallas TA; Shahin MS; Sood AK; Hatterman-Zogg M; Anderson B; Sorosky JI; Kirby PA
Clin Cancer Res; 2001 Apr; 7(4):831-8. PubMed ID: 11309330
[TBL] [Abstract][Full Text] [Related]
16. p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma.
McManus DT; Murphy M; Arthur K; Hamilton PW; Russell SE; Toner PG
J Pathol; 1996 Jun; 179(2):177-82. PubMed ID: 8758210
[TBL] [Abstract][Full Text] [Related]
17. Rat p53 gene mutations in primary Zymbal gland tumors induced by 2-amino-3-methylimidazo[4,5-f]quinoline, a food mutagen.
Makino H; Ishizaka Y; Tsujimoto A; Nakamura T; Onda M; Sugimura T; Nagao M
Proc Natl Acad Sci U S A; 1992 Jun; 89(11):4850-4. PubMed ID: 1594584
[TBL] [Abstract][Full Text] [Related]
18. Poor correlation with loss of heterozygosity on chromosome 17p and p53 mutations in ovarian cancers.
Sakamoto T; Nomura N; Mori H; Wake N
Gynecol Oncol; 1996 Nov; 63(2):173-9. PubMed ID: 8910623
[TBL] [Abstract][Full Text] [Related]
19. p53 gene mutations and protein accumulation in human ovarian cancer.
Kupryjańczyk J; Thor AD; Beauchamp R; Merritt V; Edgerton SM; Bell DA; Yandell DW
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):4961-5. PubMed ID: 8506342
[TBL] [Abstract][Full Text] [Related]
20. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China.
Gao H; Wang LD; Zhou Q; Hong JY; Huang TY; Yang CS
Cancer Res; 1994 Aug; 54(16):4342-6. PubMed ID: 8044781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
